Keros Therapeutics Strengthens TGF-β Pipeline as 2025 Financials Signal Growth

Keros Therapeutics (KROS) has solidified its position as a primary contender in the high-stakes TGF-β (transforming growth factor-beta) protein superfamily market, following the release of its fourth-quarter and full-year 2025 financial results. The company’s strategic focus on hematological and cardiovascular disorders has placed it in direct competition with industry giants, most notably Merck and Bristol Myers Squibb. The 2025 fiscal year was characterized by aggressive clinical expansion and a disciplined capital allocation strategy that has extended the company's cash runway into 2027, a critical buffer as it prepares for pivotal data readouts.

The core of Keros’s value proposition remains elritercept (KER-050), a modified activin receptor type IIA ligand trap. Throughout 2025, elritercept demonstrated compelling efficacy in treating anemia and improving hematopoiesis in patients with myelodysplastic syndromes (MDS) and myelofibrosis. This asset is positioned as a potential best-in-class alternative to Bristol Myers Squibb’s Reblozyl (luspatercept), particularly for patients who have become refractory to erythropoiesis-stimulating agents. The financial report confirms that Keros has successfully transitioned elritercept into broader Phase 2/3 trials, a move supported by the $140 million capital raise completed earlier in the year.

“

While the net loss for the year widened to approximately $165 million—reflecting increased R&D investment in late-stage trials—the company’s cash, cash equivalents, and short-term investments totaled nearly $420 million.

Simultaneously, cibotercept (KER-012) has emerged as a significant driver of shareholder value in the cardiovascular space. Targeting pulmonary arterial hypertension (PAH) and heart failure with preserved ejection fraction (HFpEF), cibotercept is navigating a market recently energized by the FDA approval of Merck’s Winrevair (sotatercept). Keros is positioning cibotercept as a differentiated therapy that may offer superior tissue remodeling benefits. The 2025 highlights indicate that the Phase 2 TROPOS trial in PAH is progressing on schedule, with top-line data expected in the second half of 2026. This timeline is crucial for Keros to establish a foothold before Merck further consolidates its dominance in the PAH sector.

Financially, Keros ended 2025 with a formidable balance sheet. While the net loss for the year widened to approximately $165 million—reflecting increased R&D investment in late-stage trials—the company’s cash, cash equivalents, and short-term investments totaled nearly $420 million. This financial stability is a significant differentiator in a biotech environment where many mid-cap peers are struggling with liquidity. The company's ability to maintain a multi-year runway while simultaneously advancing three distinct clinical programs (including the muscle-growth candidate KER-065) suggests a high level of operational efficiency.